Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 5/20 | 0.82 |
| ▸ | INSR | P06213 | 5/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857294 | 1.00 | MAPK3 (0.82) | MAPK3INSRALKLRRK2KDR | |
| SCHEMBL18857572 | 1.00 | MAPK3 (0.82) | MAPK3INSRALKLRRK2KDR | |
| SCHEMBL18857559 | 0.98 | MAPK3 (0.79) | MAPK3INSRALKLRRK2KDR | |
| SCHEMBL15938250 | 0.90 | MAPK3 (1.00) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL15938884 | 0.90 | MAPK3 (1.00) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL15938420 | 0.90 | MAPK3 (1.00) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL15938881 | 0.90 | MAPK3 (1.00) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL15938571 | 0.90 | MAPK3 (1.00) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL15937976 | 0.89 | MAPK3 (0.97) | MAPK3LRRK2KDRAURKB | |
| SCHEMBL16995451 | 0.88 | LRRK2 (0.69) | MAPK3INSRALKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885INSR 1433/4885ALK 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.